New Options for the Adjuvant Treatment of Cutaneous Melanoma?

Current Oncology Reports

Volumn 16, Issue 11, 2014, Pages 1-6

  Weise, Amy M ^a   Flaherty, Lawrence E ^a  

^a KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Biochemotherapy; Cutaneous melanoma; Melanoma; Oncology

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; DABRAFENIB; DACARBAZINE; IPILIMUMAB; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

BIOCHEMOTHERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CUTANEOUS MELANOMA; HUMAN; METASTATIC MELANOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; REVIEW; TREATMENT DURATION; ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; SKIN NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; SKIN NEOPLASMS;

EID: 84920923468     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-014-0409-x     Document Type: Review

References (17)

1. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–206.
2. Dickson PV, Gershenwald JE. Staging and prognosis of cutaneous melanoma. Surg Oncol Clin N Am. 2011;20(1):1–17.
3. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol. 1996;14(1):7–17.
4. Kirkwood JM, Manola J, Ibrahim J, et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004;10(5):1670–7.
5. Gogas H, Bafaloukos D, Ioannovich J, et al. Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year—a Hellenic Cooperative Oncology Group study. Anticancer Res. 2004;24(3b):1947–52.
6. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000;18(12):2444–58.
7. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001;19(9):2370–80.
8. Gogas H, Dafni U, Bafaloukos D, Polyzos A, Kokkalis G, Kalofonos HP, et al. A randomized phase III trial of 1 month versus 1 year adjuvant high-dose Interferon alfa-2b in patients with resected high risk melanoma. J Clin Oncol. 2007;25(18 Suppl):8505.
9. Eggermont AM, Suciu S, MacKie R, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet. 2005;366(9492):1189–96.
10. Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008;372(9633):117–26.
11. Eggermont AM, Suciu S, Testori A, et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol. 2012;30(31):3810–8.
12. Kim KB, Legha SS, Gonzalez R, et al. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res. 2009;19(1):42–9.
13. Flaherty LE, Moon J, Atkins MB, Tuthill R, Thompson JA, Vetto JT, et al. Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC, plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): an intergroup study of CALGB, COG, ECOG, and SWOG. J Clin Oncol. 2012;30(15 Suppl):8504.
14. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16.
15. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694–703.
16. Fadaki N, Cardona-Huerta S, Martineau L, et al. Inoperable bulky melanoma responds to neoadjuvant therapy with vemurafenib. BMJ Case Rep. 2012. doi:10.1136/bcr-2012-007034.
17. Koers K, Francken AB, Haanen JB, Woerdeman LA, van der Hage JA. Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma. J Clin Oncol. 2013;31(16):e251–3.